Sheng, X., Chi, Z., Cui, C., Si, L., Li, S., Tang, B., . . . Guo, J. (2016). Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: Largest single-center retrospective analysis. Oncotarget.
Citação norma ChicagoSheng, Xinan, et al. "Efficacy and Safety of Sorafenib Versus Sunitinib As First-line Treatment in Patients With Metastatic Renal Cell Carcinoma: Largest Single-center Retrospective Analysis." Oncotarget 2016.
Citação norma MLASheng, Xinan, et al. "Efficacy and Safety of Sorafenib Versus Sunitinib As First-line Treatment in Patients With Metastatic Renal Cell Carcinoma: Largest Single-center Retrospective Analysis." Oncotarget 2016.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.